Bujanover et al. USSN: 10/538,599

**Amendments to the Specification:** 

Please replace paragraph [0059] of the published application with the following amended

paragraph:

[0059] There are several basic reasons why the concept of bacteriophage therapy for human or

veterinary use has not been reduced successfully to practice: (i) the efficacy of phage therapy

was shown to be marginal or even negligible; (ii) unacceptable toxic side effects have been

observed, mainly due to the use of bacteriophage compositions contaminated with bacterial

debris typically containing toxins; (iii) better alternatives, such as conventional chemical

antibiotics, were already developed; (iv) appearance of new phage-resistant bacterial strain due

to activation of the bacterial defense system upon introduction of the phage; and (vi)(v) fast

removal of the bacteriophage from the body once the composition was injected or ingested,

before the phage could arrive at the target site. The intensive research in the field of molecular

biology, which employs bacteria and phages as a research tool, has advanced practical

knowledge on bacterial-phage interactions and revealed new techniques that may be utilized to

overcome at least part of the above described difficulties in the development of phage therapy to

a reliable therapeutic tool.

Please replace the Abstract with the amended Abstract provided herewith on a separate

sheet.

Attachment: Amended Abstract

2